Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Shares Outstanding (Diluted Average): 2018-2025

Historic Shares Outstanding (Diluted Average) for Cidara Therapeutics (CDTX) over the last 6 years, with Sep 2025 value amounting to $26.9 million.

  • Cidara Therapeutics' Shares Outstanding (Diluted Average) rose 311.67% to $26.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 311.67%. This contributed to the annual value of $6.3 million for FY2024, which is 45.25% up from last year.
  • As of Q3 2025, Cidara Therapeutics' Shares Outstanding (Diluted Average) stood at $26.9 million, which was up 72.91% from $15.5 million recorded in Q2 2025.
  • Over the past 5 years, Cidara Therapeutics' Shares Outstanding (Diluted Average) peaked at $88.6 million during Q3 2022, and registered a low of $4.4 million during Q4 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $8.8 million, with a median of $5.1 million in 2023.
  • In the last 5 years, Cidara Therapeutics' Shares Outstanding (Diluted Average) tumbled by 94.90% in 2023 and then skyrocketed by 311.67% in 2025.
  • Cidara Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $52.5 million in 2021, then surged by 33.18% to $69.9 million in 2022, then plummeted by 93.74% to $4.4 million in 2023, then surged by 45.25% to $6.3 million in 2024, then surged by 311.67% to $26.9 million in 2025.
  • Its last three reported values are $26.9 million in Q3 2025, $15.5 million for Q2 2025, and $14.2 million during Q1 2025.